ADD Drug Causes Suicidal Thoughts, Says FDA

By Elizabeth Rhein

Published on October 11, 2005

The Food and Drug Administration has issued a Public Health Advisory on Strattera (Atomoxetine) regarding the possible negative effects of the drug on young people who take it to help control ADD and ADHD. In clinical trials, 0.4 percent of those studied showed dangerous suicidal behavior or thoughts; no such cases were reported among children who took the placebo.

The FDA's advisory instructs Strattera's maker, Eli Lilly and Company, to devise a Medication Guide that will be dispensed to patients with the drug. The administration is also advising physicians, parents, and other caregivers to closely monitor children and teens who take Strattera, especially after dosage is initially begun or changed.

Caregivers with questions or concerns about Strattera are urged to contact their medical provider.

Comment on this article →